Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 191

1.

Defining the Minimally Important Change for the SpondyloArthritis Research Consortium of Canada Spine and Sacroiliac Joint Magnetic Resonance Imaging Indices for Ankylosing Spondylitis.

Maksymowych WP, Lambert RG, Brown LS, Pangan AL.

J Rheumatol. 2012 Aug;39(8):1666-74. doi: 10.3899/jrheum.120131. Epub 2012 Jul 1.

2.

Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study.

Lambert RG, Salonen D, Rahman P, Inman RD, Wong RL, Einstein SG, Thomson GT, Beaulieu A, Choquette D, Maksymowych WP.

Arthritis Rheum. 2007 Dec;56(12):4005-14.

3.

Scoring inflammatory activity of the spine by magnetic resonance imaging in ankylosing spondylitis: a multireader experiment.

Lukas C, Braun J, van der Heijde D, Hermann KG, Rudwaleit M, Østergaard M, Oostveen A, O'Connor P, Maksymowych WP, Lambert RG, Jurik AG, Baraliakos X, Landewé R; ASAS/OMERACT MRI in AS Working Group.

J Rheumatol. 2007 Apr;34(4):862-70.

PMID:
17407241
4.

Course of Magnetic Resonance Imaging-Detected Inflammation and Structural Lesions in the Sacroiliac Joints of Patients in the Randomized, Double-Blind, Placebo-Controlled Danish Multicenter Study of Adalimumab in Spondyloarthritis, as Assessed by the Berlin and Spondyloarthritis Research Consortium of Canada Methods.

Pedersen SJ, Poddubnyy D, Sørensen IJ, Loft AG, Hindrup JS, Thamsborg G, Asmussen K, Hendricks O, Nørregaard J, Piil AD, Møller JM, Jurik AG, Balding L, Lambert RG, Sieper J, Østergaard M.

Arthritis Rheumatol. 2016 Feb;68(2):418-29. doi: 10.1002/art.39434.

PMID:
26414004
5.

Spinal inflammation in the absence of sacroiliac joint inflammation on magnetic resonance imaging in patients with active nonradiographic axial spondyloarthritis.

van der Heijde D, Sieper J, Maksymowych WP, Brown MA, Lambert RG, Rathmann SS, Pangan AL.

Arthritis Rheumatol. 2014 Mar;66(3):667-73. doi: 10.1002/art.38283.

6.

Adalimumab significantly reduces inflammation and serum DKK-1 level but increases fatty deposition in lumbar spine in active ankylosing spondylitis.

Hu Z, Xu M, Li Q, Lin Z, Liao Z, Cao S, Wei Q, Zhang YL, Li T, Jin O, Huang J, Pan Y, Wu Y, Deng X, Gu J.

Int J Rheum Dis. 2012 Aug;15(4):358-65. doi: 10.1111/j.1756-185X.2012.01734.x. Epub 2012 May 23. Erratum in: Int J Rheum Dis. 2012 Dec;15(6):564.

PMID:
22898215
7.

Scoring sacroiliac joints by magnetic resonance imaging. A multiple-reader reliability experiment.

Landewé RB, Hermann KG, van der Heijde DM, Baraliakos X, Jurik AG, Lambert RG, Østergaard M, Rudwaleit M, Salonen DC, Braun J.

J Rheumatol. 2005 Oct;32(10):2050-5.

PMID:
16206369
8.

Low-dose infliximab (3 mg/kg) significantly reduces spinal inflammation on magnetic resonance imaging in patients with ankylosing spondylitis: a randomized placebo-controlled study.

Maksymowych WP, Salonen D, Inman RD, Rahman P, Lambert RG; CANDLE Study Group.

J Rheumatol. 2010 Aug 1;37(8):1728-34. doi: 10.3899/jrheum.091043. Epub 2010 May 1.

PMID:
20436073
9.

Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1).

Sieper J, van der Heijde D, Dougados M, Mease PJ, Maksymowych WP, Brown MA, Arora V, Pangan AL.

Ann Rheum Dis. 2013 Jun;72(6):815-22. doi: 10.1136/annrheumdis-2012-201766. Epub 2012 Jul 7.

10.

Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept.

Rudwaleit M, Baraliakos X, Listing J, Brandt J, Sieper J, Braun J.

Ann Rheum Dis. 2005 Sep;64(9):1305-10. Epub 2005 Mar 18. Erratum in: Ann Rheum Dis. 2005 Nov;64(11):1668.

11.

Spondyloarthritis research Consortium of Canada magnetic resonance imaging index for assessment of sacroiliac joint inflammation in ankylosing spondylitis.

Maksymowych WP, Inman RD, Salonen D, Dhillon SS, Williams M, Stone M, Conner-Spady B, Palsat J, Lambert RG.

Arthritis Rheum. 2005 Oct 15;53(5):703-9.

12.

Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors.

Pedersen SJ, Sørensen IJ, Hermann KG, Madsen OR, Tvede N, Hansen MS, Thamsborg G, Andersen LS, Majgaard O, Loft AG, Erlendsson J, Asmussen K, Johansen JS, Jurik AG, Møller J, Hasselquist M, Mikkelsen D, Skjødt T, Hansen A, Ostergaard M.

Ann Rheum Dis. 2010 Jun;69(6):1065-71. doi: 10.1136/ard.2009.111187. Epub 2009 Sep 9.

PMID:
19740906
13.

Is there a preferred method for scoring activity of the spine by magnetic resonance imaging in ankylosing spondylitis?

van der Heijde D, Landewé R, Hermann KG, Rudwaleit M, Østergaard M, Oostveen A, O'Connor P, Maksymowych WP, Lambert RG, Lukas C, Jurik AG, Boers M, Baraliakos X, Braun J; ASAS/OMERACT MRI in AS Working Group.

J Rheumatol. 2007 Apr;34(4):871-3.

PMID:
17407242
14.

Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system.

Braun J, Baraliakos X, Golder W, Brandt J, Rudwaleit M, Listing J, Bollow M, Sieper J, Van Der Heijde D.

Arthritis Rheum. 2003 Apr;48(4):1126-36.

15.

MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis.

Rudwaleit M, Schwarzlose S, Hilgert ES, Listing J, Braun J, Sieper J.

Ann Rheum Dis. 2008 Sep;67(9):1276-81. Epub 2007 Nov 15.

PMID:
18006539
16.

Validation of whole-body against conventional magnetic resonance imaging for scoring acute inflammatory lesions in the sacroiliac joints of patients with spondylarthritis.

Weber U, Maksymowych WP, Jurik AG, Pfirrmann CW, Rufibach K, Kissling RO, Khan MA, Lambert RG, Hodler J.

Arthritis Rheum. 2009 Jul 15;61(7):893-9. doi: 10.1002/art.24542.

17.

Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial.

Haibel H, Rudwaleit M, Brandt HC, Grozdanovic Z, Listing J, Kupper H, Braun J, Sieper J.

Arthritis Rheum. 2006 Feb;54(2):678-81. No abstract available.

18.

MRI inflammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a tumour necrosis factor inhibitor.

Machado P, Landewé RB, Braun J, Baraliakos X, Hermann KG, Hsu B, Baker D, van der Heijde D.

Ann Rheum Dis. 2012 Dec;71(12):2002-5. doi: 10.1136/annrheumdis-2012-201999. Epub 2012 Aug 21.

PMID:
22915615
19.

The time-averaged inflammatory disease activity estimates the progression of erosions in MRI of the sacroiliac joints in ankylosing spondylitis.

Wick MC, Grundtman C, Weiss RJ, Gruber J, Kastlunger M, Jaschke W, Klauser AS.

Clin Rheumatol. 2012 Jul;31(7):1117-21. doi: 10.1007/s10067-012-1973-9. Epub 2012 Mar 16.

PMID:
22422197
20.

Metric Properties of the SPARCC Score of the Sacroiliac Joints - Data from Baseline, 3-month, and 12-month Followup in the SPACE Cohort.

van den Berg R, de Hooge M, Bakker PA, van Gaalen F, Navarro-Compán V, Fagerli KM, Landewé R, van Oosterhout M, Ramonda R, Reijnierse M, van der Heijde D.

J Rheumatol. 2015 Jul;42(7):1186-93. doi: 10.3899/jrheum.140806. Epub 2015 May 1.

PMID:
25934824
Items per page

Supplemental Content

Write to the Help Desk